Four months after securing $125 million in funding, SpringWorks Therapeutics is eying another $115 million from a potential initial public offering.
Rare Cancer Treatments and the Power of Checkpoint Inhibitors Among Hot Topics at ASCO
American Society of Clinical Oncology (ASCO), Blockbusters, Cancer, Checkpoint Inhibitors, Clinical Studies, Clinical Trials, Data, Desmoid Tumors, Endocrine Therapy, Gastroenteropancreatic neuroendocrine tumors, Lung Cancer, Nobel Prize, Nobel Prize in Physiology or Medicine, Orphan Diseases, PD-L1 Inhibitor, PD-L1 protein, PIK3CA mutations, R&D, Rare Cancers, Rare Sarcomas, Tenosynovial Giant Cell Tumor (TGCT)With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.
